A device for metastatic cancers

Viatar is at the bleeding edge of innovation - It's a cancer dialysis med-tech  focused on the treatment of patients making metastatic cancers a chronic rather than fatal condition.

Click here for an animated video of how it works - http://www.mediafire.com/download/xb4avvy8i4vd4di/VTO_A2.mov

Viatar is looking to be listed in the ASX listed on 26 July 2016 raising $13.6m.

We are hosting a lunch with Viatar's leader Ilan Reich on Friday 1 July. With Viatar's founder, Ilan Reich 

( see http://www.viatarctcsolutions.com/ir-management.html) 

Viatar’s value proposition is

 - proven technology for removal of over 90% of a cancer patient’s lethal circulating tumor cells

   - few competitors and a more effective and affordable devices

- pivotal US trial results imminent, major regulatory approvals in US and commercialization in Europe 2016

   - a sophisticated and supportive investor based of over 100, and in excess of USD 21M in funding to date

   - a large growing market with regulated growth drivers and existing reimbursement regime in the US

- An ASX listing broadens Viatar’s stakeholder base to support global play with uplift to NASDAQ potential, Q4 ‘16. 

(www.viatarctcsolutions.com),

( Contact me if interested and I will refer you to the powers that be)